Medtronic (MDT) announced FDA clearance for its new InPen app featuring missed meal dose detection, paving the way for the launch of its Smart MDI system with the Simplera continuous glucose monitor, or CGM. The company’s Smart MDI system combines its InPen smart insulin pen with its newest Simplera(TM) CGM – the company’s first disposable, all-in-one CGM that’s half the size of previous Medtronic CGMs. With this clearance, the system will be the first in the market to recommend corrections for missed or inaccurate insulin doses, providing real-time, personalized insights for individuals on multiple daily injection therapy. Medtronic will initiate a limited market release beginning with existing standalone CGM and InPen customers followed by a broad commercial launch.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Medtronic price target raised to $97 from $96 at Bernstein
- Medtronic price target lowered to $93 from $96 at Baird
- Medtronic price target lowered to $98 from $106 at Wells Fargo
- Medtronic Reports Strong Q2 2025 Results, Raises Guidance
- Trump Trade: President-elect seeks to kill Biden fuel-efficiency rules